Dashboard
1
With a growth in Operating Profit of 245.89%, the company declared Very Positive results in Mar 25
- RAW MATERIAL COST(Y) Fallen by -65.66% (YoY)
- NET SALES(Q) Highest at CNY 290.79 MM
- OPERATING PROFIT(Q) Highest at CNY 38.93 MM
2
With ROE of 3.15%, it has a fair valuation with a 1.80 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,187 Million (Small Cap)
57.00
NA
0.50%
-0.02
3.15%
1.80
Revenue and Profits:
Net Sales:
194 Million
(Quarterly Results - Jun 2025)
Net Profit:
6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
51.14%
0%
51.14%
6 Months
51.31%
0%
51.31%
1 Year
42.84%
0%
42.84%
2 Years
-17.32%
0%
-17.32%
3 Years
-58.18%
0%
-58.18%
4 Years
-6.15%
0%
-6.15%
5 Years
-0.38%
0%
-0.38%
Teyi Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.06%
EBIT Growth (5y)
-15.09%
EBIT to Interest (avg)
8.54
Debt to EBITDA (avg)
0.88
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.40
Tax Ratio
14.65%
Dividend Payout Ratio
121.95%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.69%
ROE (avg)
9.04%
Valuation key factors
Factor
Value
P/E Ratio
57
Industry P/E
Price to Book Value
1.80
EV to EBIT
49.79
EV to EBITDA
24.21
EV to Capital Employed
1.81
EV to Sales
3.69
PEG Ratio
NA
Dividend Yield
0.50%
ROCE (Latest)
3.64%
ROE (Latest)
3.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
193.90
147.40
31.55%
Operating Profit (PBDIT) excl Other Income
25.20
4.20
500.00%
Interest
1.20
2.00
-40.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
6.40
-6.50
198.46%
Operating Profit Margin (Excl OI)
40.50%
-79.70%
12.02%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 31.55% vs -36.44% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 198.46% vs -113.92% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
679.70
1,054.90
-35.57%
Operating Profit (PBDIT) excl Other Income
91.20
366.80
-75.14%
Interest
5.90
16.80
-64.88%
Exceptional Items
-11.60
-13.20
12.12%
Consolidate Net Profit
20.50
253.20
-91.90%
Operating Profit Margin (Excl OI)
40.20%
290.70%
-25.05%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -35.57% vs 20.33% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -91.90% vs 42.09% in Dec 2023
About Teyi Pharmaceutical Group Co., Ltd. 
Teyi Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






